2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
King B, Ko J, Kwon O, Vañó-Galván S, Piraccini B, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska N. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata. JAMA Dermatology 2024, 160 PMID: 39141364, PMCID: PMC11325239, DOI: 10.1001/jamadermatol.2024.2734.Peer-Reviewed Original ResearchSevere alopecia areataProportion of patientsAlopecia areataHair regrowthSevere AATreatment benefitWeeks of treatment withdrawalClinical trialsPhase 3 randomized clinical trialLoss of treatment benefitRandomized withdrawal periodDose of baricitinibRerandomized to placeboWithdrawal of therapyFollow-up observation periodYear of treatmentRandomized clinical trialsWithdrawal periodRelapsing conditionBaricitinib doseRecapture responsePlacebo-controlledSALT scoreContinuous therapyDose groupVisualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
Mesinkovska N, King B, Vañó‐Galván S, Shimomura Y, Jedynak J, McCollam J, Pierce E, Ellinwood A, Sinclair R. Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial. JEADV Clinical Practice 2024, 3: 528-535. DOI: 10.1002/jvc2.327.Peer-Reviewed Original ResearchSeverity of Alopecia Tool scoreSeverity of Alopecia ToolSALT scoreAlopecia areataClinical trialsSevere AAPatient imagesTime of clinical responseEligibility criteriaClinical trials of adultsWeeks of therapyHair lossPhase 2/3 studyClinical settingTrials of adultsCourse of treatmentPattern of hair lossClinical responseSystemic treatmentFemale patientsTherapeutic responseTreatment decisionsPatientsMonitor treatment progressClinicians
2022
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi G, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang F, Stanley S, Wu W, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal Of Dermatology 2022, 188: 218-227. PMID: 36763878, DOI: 10.1093/bjd/ljac059.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsSevere alopecia areataPlacebo-controlled periodAlopecia areataIncidence rateIntegrated safety analysisCreatine phosphokinaseBaricitinib 2Adverse eventsIII trialsClinical trialsSafety dataPhase II/III trialsMajor adverse cardiovascular eventsUpper respiratory tract infectionLong-term extension periodAbnormal laboratory changesDose of baricitinibElevated creatine phosphokinaseAdverse cardiovascular eventsPhase III trialsProportion of patientsRespiratory tract infectionsBlood creatine phosphokinaseOverall safety profileEfficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, Hamzavi I, Ganesan A, Picardo M, Thaçi D, Harris J, Bae J, Tsukamoto K, Sinclair R, Pandya A, Sloan A, Yu D, Gandhi K, Vincent M, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal Of The American Academy Of Dermatology 2022, 88: 395-403. PMID: 36370907, DOI: 10.1016/j.jaad.2022.11.005.Peer-Reviewed Original ResearchConceptsNonsegmental vitiligoLoading doseScoring IndexPercent changePhase 2b clinical trialExtension periodPhase 2b trialPrimary efficacy endpointSerious adverse eventsChronic autoimmune disorderDose-dependent trendEfficacy endpointAdverse eventsWeek 24Autoimmune disordersClinical trialsStable vitiligoPatientsVitiligoSignificant differencesTreatmentDoseBaselineTrialsWeeks33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials
King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Holzwarth K, Issa M, Dutronc Y, Stanley S, Wu W, Sinclair R. 33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials. Journal Of The American Academy Of Dermatology 2022, 87: ab176. DOI: 10.1016/j.jaad.2022.06.737.Peer-Reviewed Original Research
2021
27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials
King B, Maari C, Lain E, Silverberg J, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes F, Simpson E. 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials. Journal Of The American Academy Of Dermatology 2021, 85: ab127. DOI: 10.1016/j.jaad.2021.06.525.Peer-Reviewed Original Research
2020
16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials
Simpson E, Gooderham M, King B, Taylor S, Rosmarin D, Tatulych S, Nduaka C, Williams D, Zhang W, Rojo R. 16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials. Journal Of The American Academy Of Dermatology 2020, 83: ab62. DOI: 10.1016/j.jaad.2020.06.336.Peer-Reviewed Original ResearchDevelopment of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal Of Clinical Dermatology 2020, 21: 725-732. PMID: 32803546, PMCID: PMC7473969, DOI: 10.1007/s40257-020-00545-9.Peer-Reviewed Original ResearchConceptsSigns/symptomsAlopecia areataPRO measuresNail appearanceEyelash lossOutcome measuresHair lossEye irritationPatient-reported outcome measuresClinician-reported outcomesNorth American patientsDevelopment of cliniciansNail assessmentEyebrow lossNail involvementAmerican patientsClinical trialsPatientsNail damageSymptomsAreataObjectivesOur objectiveOutcomesEyelashesDermatologistsThe Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal Of Dermatology 2020, 183: 702-709. PMID: 31970750, PMCID: PMC7586961, DOI: 10.1111/bjd.18883.Peer-Reviewed Original ResearchConceptsInvestigator's Global AssessmentScalp hair lossAlopecia areataTreatment successGlobal assessmentAlopecia ToolClinical trialsClinician's perspectiveScalp hairTreatment studiesInvestigator's Global Assessment (IGA) scaleSigns/symptomsScalp hair growthGlobal Assessment ScaleMost patientsAdolescent patientsHair regrowthClinical evaluationExpert dermatologistsSuccessful treatmentClinical consensusTreatment outcomesPatient insightTreatment responseAdditional clinicians
2016
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2016, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.Peer-Reviewed Original ResearchConceptsAlopecia areataAdverse eventsAdolescent patientsTreatment of AASignificant hair regrowthUse of tofacitinibMonths of treatmentProspective clinical trialsMedian percent changeJanus kinase inhibitorSeverity of diseaseReview of systemsSALT scoreAlopecia ToolLaboratory monitoringPhysical examinationHair regrowthClinical trialsEffective therapyPromising therapyRetrospective natureTofacitinibControl groupPatientsPercent change